Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of “Moderate Buy” from Analysts

by · The Markets Daily

Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Free Report) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $42.60.

Several analysts recently weighed in on the company. StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. HC Wainwright increased their target price on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Finally, Piper Sandler restated a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th.

Read Our Latest Report on COLL

Collegium Pharmaceutical Trading Down 0.3 %

Shares of NASDAQ COLL opened at $29.06 on Thursday. The stock has a market capitalization of $937.19 million, a P/E ratio of 12.53 and a beta of 0.80. Collegium Pharmaceutical has a 1-year low of $28.75 and a 1-year high of $42.29. The business’s 50 day moving average is $32.12 and its two-hundred day moving average is $34.27. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in COLL. nVerses Capital LLC boosted its position in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC raised its stake in shares of Collegium Pharmaceutical by 124.5% during the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 792 shares in the last quarter. CWM LLC boosted its holdings in shares of Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after purchasing an additional 736 shares during the period. TD Private Client Wealth LLC grew its stake in Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares in the last quarter. Finally, Virtus Fund Advisers LLC purchased a new position in Collegium Pharmaceutical during the 3rd quarter worth $72,000.

About Collegium Pharmaceutical

(Get Free Report

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Further Reading